Ferring Pharmaceuticals products

MINIRIN® (desmopressin) is indicated for the treatment of bedwetting in children and nocturia in adults. Both conditions are usually caused by an overproduction of urine at night, and MINIRIN acts on the kidneys to reduce this. Bedwetting can be traumatic for children, affecting their well-being and self-esteem. For adults with nocturia, waking up several times a night to urinate can lead to sleep deprivation affecting a patient’s quality of life.

NOCDURNA® (desmopressin) is indicated for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. Nocturia, the need to awaken at night to pass urine, is a complex medical condition with various contributing factors. The night-time overproduction of urine, nocturnal polyuria, is responsible for nocturia in up to 88% of cases. NOCDURNA® once-daily lyophilisate tablets are administered sublingually (without the need for water) in gender specific low doses, tailored specifically for men (50 mcg) and women (25 mcg).

FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly used. Decreasing testosterone levels can cause the cancer cells to die, thus reducing the size of the tumour and delaying its growth. To date, FIRMAGON has been approved in 74 countries.